Multiple Myeloma Drugs Market Report 2026

The multiple myeloma drugs market size has grown strongly in recent years. It will grow from $23.03 billion in 2025 to $24.4 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increasing prevalence of multiple myeloma, approval of novel immunomodulatory drugs, rising awareness about plasma cell cancers, development of proteasome inhibitors, expansion of hospital pharmacy networks.

The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to $31.61 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growth in precision medicine adoption, rising investment in biologic therapies, increase in geriatric population, expansion of online pharmacy distribution, advancements in monoclonal antibody treatments. Major trends in the forecast period include personalized therapy development, combination drug regimens, bone health management in multiple myeloma, targeted drug delivery systems, clinical trial expansion.

The rising prevalence of hematological cancers is expected to propel the growth of the multiple myeloma drugs market in the coming years. Hematological cancers originate in blood-forming tissues such as bone marrow or in cells of the immune system and include conditions such as leukemia, lymphoma, and multiple myeloma. Drugs used for multiple myeloma are designed to treat the disease by killing cancer cells or inhibiting their growth through the suppression of cell division, modulation of enzymatic pathways, strengthening of bones, and reduction of bone-related pain. For example, in January 2023, according to the American Cancer Society, there were approximately 59,610 newly diagnosed cases of leukemia in the United States, including around 20,380 cases of acute myeloid leukemia, with a total of about 23,710 deaths attributed to leukemia. Therefore, the increasing burden of hematological cancers is driving the growth of the multiple myeloma drugs market.

Companies operating in the multiple myeloma drugs market are increasingly strengthening their partnership strategies to co-develop advanced cell therapies, particularly by expanding collaborations to accelerate the development and commercialization of next-generation CAR T-cell products. Strategic partnerships allow companies to share resources, reduce development risks, and speed up the scaling of innovative therapies. For instance, in May 2024, Kite Pharma and Arcellx, Inc. announced key operational updates for their partnered BCMA-targeted CAR T therapy, anitocabtagene autoleucel. The companies disclosed the design of a global Phase 3 clinical trial, named iMMagine 3, which is set to evaluate the therapy in patients with relapsed or refractory multiple myeloma who have previously been treated with an immunomodulatory drug and an anti-CD38 monoclonal antibody. The trial is expected to enroll approximately 450 patients worldwide.

In October 2024, the International Myeloma Foundation partnered with SparkCures to improve clinical trial navigation and expand patient access to investigational multiple myeloma therapies. Through this collaboration, the International Myeloma Foundation aims to enhance patient access to relevant clinical trials by integrating SparkCures’ trial-matching technology into its platform, enabling personalized trial discovery based on individual diagnoses, treatment histories, and patient preferences.

Major companies operating in the multiple myeloma drugs market are Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Onyx Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., PharmaMar SA.

North America was the largest region in the multiple myeloma drugs market in 2025. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multiple myeloma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the multiple myeloma drugs market by disrupting the import of active pharmaceutical ingredients and specialty compounds, leading to increased production costs. The impact is most significant on segments like immunomodulatory drugs and monoclonal antibodies, particularly in regions heavily dependent on imports such as North America and Europe. While tariffs may temporarily slow market growth, they are also encouraging local manufacturing and supply chain diversification, which could enhance domestic production capabilities and innovation in drug development.

The multiple myeloma drugs market research report is one of a series of new reports that provides multiple myeloma drugs market statistics, including multiple myeloma drugs industry global market size, regional shares, competitors with a multiple myeloma drugs market share, detailed multiple myeloma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma drugs industry. This multiple myeloma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multiple myeloma drugs are medications used to treat multiple myeloma, a cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. These drugs are also used to manage bone-related complications associated with the disease, including treatments such as pamidronate (Aredia) and zoledronic acid (Zometa).

The main classes of multiple myeloma drugs include immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors, monoclonal antibody drugs, steroids, and others. Targeted therapy is a form of cancer treatment that uses drugs or compounds designed to specifically target molecules that are essential for cancer cell growth and survival. In multiple myeloma, targeted therapy focuses on particular proteins on or within cancer cells, interfering with signaling pathways that control cell growth and division. Treatment approaches include targeted therapy, biologic therapy, chemotherapy, and others, and these drugs are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used in both men and women.

The multiple myeloma drugs market consists of revenues earned by entities by providing various therapies such radiation therapy, bone-marrow transplant, surgery and stem-cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma drug market also includes sales of nuclear export inhibitors, bispecific T cell engager (BiTE), bisphosphonates, and alkylating agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.